Biothera Pharmaceuticals Inc. is a mid clinical-stage biotechnology company advancing Imprime PGG, a first-in-class, systemically administered beta glucan PAMP (pathogen associated molecular pattern). Imprime PGG acts as an immunological “ignition switch,” triggering a robust, coordinated immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies (e.g., Avastin®), and tumor-targeting monoclonal antibodies (e.g., Erbitux®). Imprime PGG is the most advanced PAMP in immune-oncology, with a strong safety profile in 400+ patients and established proof of concept in single arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer (mCRC), and chronic lymphocytic leukemia (CLL). Imprime PGG has broad intellectual property protections, with more than 100 issued and pending patients in the US and internationally.
Biothera Pharmaceuticals is a subsidiary of Biothera Holding Corp., a privately held company.
Company Growth (employees)